2015
Role of GABA Deficit in Sensitivity to the Psychotomimetic Effects of Amphetamine
Ahn KH, Sewell A, Elander J, Pittman B, Ranganathan M, Gunduz-Bruce H, Krystal J, D'Souza DC. Role of GABA Deficit in Sensitivity to the Psychotomimetic Effects of Amphetamine. Neuropsychopharmacology 2015, 40: 2822-2831. PMID: 25953357, PMCID: PMC4864658, DOI: 10.1038/npp.2015.132.Peer-Reviewed Original ResearchConceptsGABA deficitHealthy subjectsPsychotomimetic effectsIntravenous infusionSchizophrenia patientsPANSS positive symptoms subscaleDouble-blind crossover designStriatal dopamine releasePositive symptom subscaleAdministration of drugsDose of AMPHPartial inverse agonistSubclinical responsePharmacokinetic interactionsSubthreshold doseDopamine releaseBenzodiazepine receptorsSymptom subscalesCrossover designCADSS scoresPositive symptomsAMPHInverse agonistSubjective effectsTest day
1997
Benzodiazepine Receptor Antagonists
Abi-Dargham A, Charney D, Krystal J. Benzodiazepine Receptor Antagonists. CNS Drugs 1997, 8: 244-256. DOI: 10.2165/00023210-199708030-00007.Peer-Reviewed Original ResearchBenzodiazepine receptorsIdiopathic recurrent stuporBenzodiazepine receptor antagonistPotential therapeutic benefitBenzodiazepine toleranceCerebral ischaemiaGABAergic systemΓ-aminobutyric acidReceptor antagonistMovement disordersNeuronal markersSleep disordersTherapeutic benefitCognitive disordersPotential treatmentNeuropsychiatric illnessOnly agentInverse agonistFlumazenilPharmacological investigationsAdverse effectsReceptorsDisordersImaging agentEpilepsy